HealthQuiet 23d · day 24
Novartis' oral MS pill remibrutinib clears two Phase 3 trials, shares jump
The company's oral drug cut relapse rates and outperformed a rival treatment in late-stage relapsing multiple sclerosis studies.
What to know
- Remibrutinib, Novartis' oral multiple sclerosis drug, met its primary endpoint in two separate Phase 3 trials for relapsing MS.
- The drug reduced relapse rates and outperformed an existing rival treatment in head-to-head comparisons.
- Some reporting suggests the drug may also have a better safety profile than rival MS treatments.
- Novartis shares rose following the disclosure of the trial results, reflecting investor optimism about the company's pipeline.
Novartis Pharmaceutical company developing remibrutinib
The record 8 articles and posts · last 24 days